Generics in North America
Generics in North America
SUMMARY
Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The North American generics market had total revenues of $120.7bn in 2019, representing a compound annual growth rate (CAGR) of 4% between 2015 and 2019.
- Market consumption volume increased with a CAGR of 1.2% between 2015 and 2019, to reach a total of 85.9 % in 2019.
- The huge size of the US market means that it made up over 90% of the value of the North American region in 2019
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in North America
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in North America
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the North America generics market with five year forecasts by both value and volume
- What was the size of the North America generics market by value in 2019?
- What will be the size of the North America generics market in 2024?
- What factors are affecting the strength of competition in the North America generics market?
- How has the market performed over the last five years?
- How large is North America’s generics market in relation to its regional counterparts?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.
9 APPENDIX
9.1. Methodology
9.2. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.
9 APPENDIX
9.1. Methodology
9.2. About MarketLine
LIST OF TABLES
Table 1: North America generics market value: $ billion, 2015-19
Table 2: North America generics market volume: % of total pharma, 2015-19
Table 3: North America generics market geography segmentation: $ billion, 2019
Table 4: North America generics market value forecast: $ billion, 2019-24
Table 5: North America generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 1: North America generics market value: $ billion, 2015-19
Table 2: North America generics market volume: % of total pharma, 2015-19
Table 3: North America generics market geography segmentation: $ billion, 2019
Table 4: North America generics market value forecast: $ billion, 2019-24
Table 5: North America generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
LIST OF FIGURES
Figure 1: North America generics market value: $ billion, 2015-19
Figure 2: North America generics market volume: % of total pharma, 2015-19
Figure 3: North America generics market geography segmentation: % share, by value, 2019
Figure 4: North America generics market value forecast: $ billion, 2019-24
Figure 5: North America generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in North America, 2019
Figure 7: Drivers of buyer power in the generics market in North America, 2019
Figure 8: Drivers of supplier power in the generics market in North America, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in North America, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in North America, 2019
Figure 11: Drivers of degree of rivalry in the generics market in North America, 2019
Figure 1: North America generics market value: $ billion, 2015-19
Figure 2: North America generics market volume: % of total pharma, 2015-19
Figure 3: North America generics market geography segmentation: % share, by value, 2019
Figure 4: North America generics market value forecast: $ billion, 2019-24
Figure 5: North America generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in North America, 2019
Figure 7: Drivers of buyer power in the generics market in North America, 2019
Figure 8: Drivers of supplier power in the generics market in North America, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in North America, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in North America, 2019
Figure 11: Drivers of degree of rivalry in the generics market in North America, 2019